Actelion

Actelion is a Swiss biopharmaceutical company. Actelion's main product is the anti-pulmonary arterial hypertension drug Tracleer, and it has launched a new drug for treating lung cancer. Its key products include Tracleer, an orally administered dual endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disease that severely impairs lung and heart function; and Zavesca, licensed from Oxford GlycoSciences, an oral medication used for the treatment of adult patients with mild to moderate Type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analog of prostacyclin, which induces potent pulmonary vasodilation and inhibits platelet aggregation.